
Over the last 7 days, the Clinical Research and Equipment industry has dropped 1.9%, driven by declines in EirGenix and Locus Cell of 2.0% and 2.6%, respectively. However, the industry is down 5.6% over the past year.
Has the Taiwanese Clinical Research and Equipment Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sun, 24 May 2026 | NT$32.0b | NT$2.7b | -NT$746,869,000.00 | 20.9x | -42.9x | 12.1x |
| Tue, 21 Apr 2026 | NT$36.5b | NT$2.5b | -NT$767,980,000.00 | 21.5x | -47.6x | 14.6x |
| Thu, 19 Mar 2026 | NT$32.4b | NT$2.5b | -NT$747,966,000.00 | 20.4x | -43.3x | 12.9x |
| Sat, 14 Feb 2026 | NT$33.3b | NT$2.4b | -NT$689,929,000.00 | 23.8x | -48.3x | 13.7x |
| Mon, 12 Jan 2026 | NT$34.0b | NT$2.4b | -NT$689,929,000.00 | 25.2x | -49.3x | 14x |
| Wed, 10 Dec 2025 | NT$38.0b | NT$2.4b | -NT$670,921,000.00 | 19.6x | -56.7x | 15.5x |
| Fri, 07 Nov 2025 | NT$36.0b | NT$2.5b | -NT$870,437,000.00 | 17.6x | -41.4x | 14.7x |
| Sun, 05 Oct 2025 | NT$38.3b | NT$2.5b | -NT$870,437,000.00 | 19.5x | -44.1x | 15.6x |
| Tue, 02 Sep 2025 | NT$34.9b | NT$2.5b | -NT$819,216,000.00 | 20.5x | -42.6x | 14.2x |
| Thu, 31 Jul 2025 | NT$34.0b | NT$2.5b | -NT$600,003,000.00 | 21.8x | -56.7x | 13.8x |
| Sat, 28 Jun 2025 | NT$33.5b | NT$2.5b | -NT$600,003,000.00 | 23.3x | -55.8x | 13.6x |
| Mon, 26 May 2025 | NT$31.7b | NT$2.5b | -NT$604,301,000.00 | 22.2x | -52.4x | 12.9x |
| Wed, 23 Apr 2025 | NT$30.8b | NT$2.5b | -NT$540,128,000.00 | 23.4x | -57x | 12.5x |
| Fri, 21 Mar 2025 | NT$36.8b | NT$2.4b | -NT$560,979,000.00 | 28.7x | -65.7x | 15.3x |
| Sun, 16 Feb 2025 | NT$37.4b | NT$2.6b | -NT$854,432,000.00 | 23.5x | -43.8x | 14.6x |
| Tue, 14 Jan 2025 | NT$36.3b | NT$2.6b | -NT$854,432,000.00 | 23.4x | -42.4x | 14.1x |
| Thu, 12 Dec 2024 | NT$36.2b | NT$2.6b | -NT$854,432,000.00 | 23.9x | -42.4x | 14.1x |
| Sat, 09 Nov 2024 | NT$42.0b | NT$2.5b | -NT$712,402,000.00 | 24x | -59x | 16.7x |
| Mon, 07 Oct 2024 | NT$41.6b | NT$2.3b | -NT$836,610,000.00 | 22.3x | -49.7x | 18.3x |
| Wed, 04 Sep 2024 | NT$41.1b | NT$2.3b | -NT$836,610,000.00 | 21.8x | -49.1x | 18.1x |
| Fri, 02 Aug 2024 | NT$42.9b | NT$2.1b | -NT$797,765,000.00 | 32.7x | -53.7x | 20.1x |
| Sun, 30 Jun 2024 | NT$44.0b | NT$2.1b | -NT$797,765,000.00 | 34.4x | -55.1x | 20.6x |
| Tue, 28 May 2024 | NT$39.9b | NT$2.1b | -NT$797,765,000.00 | 32.5x | -50x | 18.7x |
| Thu, 25 Apr 2024 | NT$39.0b | NT$2.1b | -NT$923,759,000.00 | 30.6x | -42.2x | 18.5x |
| Sat, 23 Mar 2024 | NT$40.2b | NT$2.1b | -NT$606,177,000.00 | 31.3x | -66.4x | 19.4x |
| Mon, 19 Feb 2024 | NT$44.3b | NT$2.1b | -NT$610,218,000.00 | 32.9x | -72.5x | 21.3x |
| Wed, 17 Jan 2024 | NT$45.2b | NT$2.1b | -NT$610,218,000.00 | 33.4x | -74.2x | 21.8x |
| Fri, 15 Dec 2023 | NT$48.8b | NT$2.1b | -NT$610,218,000.00 | 32.8x | -79.9x | 23.5x |
| Sun, 12 Nov 2023 | NT$48.2b | NT$2.2b | -NT$497,769,000.00 | 31.7x | -96.9x | 21.7x |
| Tue, 10 Oct 2023 | NT$48.3b | NT$2.2b | -NT$497,769,000.00 | 31.4x | -97.1x | 21.7x |
| Thu, 07 Sep 2023 | NT$43.3b | NT$2.2b | -NT$497,769,000.00 | 31.6x | -87x | 19.5x |
| Sat, 05 Aug 2023 | NT$47.1b | NT$2.4b | -NT$281,587,000.00 | 44.7x | -167.4x | 19.3x |
| Mon, 03 Jul 2023 | NT$50.2b | NT$2.5b | -NT$274,767,000.00 | 44x | -182.6x | 20.5x |
| Wed, 31 May 2023 | NT$49.7b | NT$2.5b | -NT$262,467,000.00 | 43.9x | -189.5x | 20.1x |
-189.5x
How does Taiwanese Clinical Research and Equipment compare with similar industries?
| TW Market | 2.64% | |
| Healthcare | 1.16% | |
| Life Sciences | -1.94% | |
| Clinical Research and Equipment | -1.94% | |
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 4133 Abnova (Taiwan) | NT$21.30 | 2.4% +NT$30.3m | -27.9% | PE671.8x | |
| 6661 Welgene BiotechLtd | NT$17.85 | 3.8% +NT$15.1m | -15.8% | PS1.1x | |
| 6848 RBC Bioscience | NT$19.55 | 1.0% +NT$2.6m | 15.6% | PE10.8x |